Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | CNR1 | P21554 | 7/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18522970 | 0.94 | TLR8 (0.36) | LTB4RLTB4R2NR1H4TLR8 | |
| SCHEMBL21783863 | 0.86 | — | — | |
| SCHEMBL19363801 | 0.84 | TLR8 (0.32) | CNR2CNR1TLR8 | |
| SCHEMBL19363951 | 0.84 | TLR8 (0.32) | CNR2CNR1TLR8 | |
| SCHEMBL19363812 | 0.84 | TLR8 (0.32) | CNR2CNR1TLR8 | |
| SCHEMBL23583873 | 0.83 | CNR2 (0.42) | CNR2CNR1LTB4RLTB4R2 | |
| SCHEMBL21166112 | 0.82 | TLR8 (0.34) | CNR2CNR1TLR8 | |
| SCHEMBL18516932 | 0.81 | CNR2 (0.45) | CNR2CNR1LTB4RLTB4R2 | |
| SCHEMBL21783862 | 0.81 | TLR8 (0.31) | TLR8 | |
| SCHEMBL20031361 | 0.81 | TLR8 (0.31) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | AMGEN INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | CNR2 144/4885CNR1 113/4885LTB4R 261/4885 |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | FABP3, TNNI3, APLNR | CNR2 204/4885CNR1 240/4885LTB4R 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.